人呼吸道合胞病毒感染的预防和治疗研究进展

Advances on Prevention and Treatment of Human Respiratory Syncytial Virus

呼吸道合胞病毒(respiratory syncytial virus,RSV)会引起呼吸道和肺部感染,尤其是婴幼儿和老人,容易出现严重感染。尽管RSV感染对医疗保健产生了全球性影响,目前仍以支持性的治疗为主。在过去的几十年中,随着对RSV发病机制和免疫病理学的了解不断加深,RSV的预防策略取得了重大进步。自1966年RSV疫苗首次试验以来已经过去50多年,目前有两种RSV疫苗获批上市。综述了当前RSV感染的治疗方案(包括RSV特异性和非特异性)以及RSV疫苗的研发进展,以期为RSV的治疗及疫苗的研发提供参考。

Respiratory syncytial virus(RSV)is a leading cause of respiratory and lung infections,especially in young children and the elderly,which are prone to serious infections.Despite the global impact of RSV infection on healthcare,the current ther⁃apy is still mostly supportive.Over the past few decades,our understanding of the pathogenesis and immunopathology of RSV had evolved,leading to significant advances in RSV prevention strategies.More than 50 years have passed since the RSV vac⁃cine was first trialed in 1966,and two RSV vaccines have been approved.In this paper,current treatment options for RSV infec⁃tion(including RSV-specific and non-specific)and the development progress of different RSV prevention vaccines were re⁃viewed,which was expected to provide reference for the treatment and vaccines research and development of RSV.